

RESEARCH AND REVIEWS: JOURNAL OF ENGINEERING AND TECHNOLOGY

Genetic syndromes and Involvement of Gene Therapy

Navya Patlolla*

Department of Biochemistry, Osmania University, India

Commentary

Received: 08/02/2015

Accepted: 09/03/2015

Published:15/03/2015

*For Correspondence

Navya Patlolla ,Department of Biochemistry, Osmania University, India

Gene therapy is a trial strategy that uses qualities to treat or anticipate infection. Later on, this strategy may permit specialists to treat an issue by embedding's a quality into an understanding's cells as opposed to utilizing medications or surgery. Expression vectors are used in quality treatment for creating particular proteins [1]. A large portion of the customary systems to treat infections have not been giving tasteful results, so at present there is expanding concentrate on gene therapy to treat wide assortment of acquired and inherited diseases [2,3].

The mammalian artificial chromosomes (MACs) have been considered as different options for viral vectors for gene therapy applications [4]. Current gene therapy techniques incorporate focusing of retroviral vectors to particular cells or tissues at the level of cell passage by altering envelope proteins so as to convey utilitarian qualities or repairing sequences [5]. Prodrug tumor suicide quality treatment coordinated to the tumor site by mesenchymal stem/stromal cells (MSCs) may be one probability to treat cancer [6-8]. The hypothesis is upheld by new proof of an autosomal prevailing type of LVNC in people created by a change in the mindbomb homolog1 (MIB1) quality encoding a protein which directs cell expansion and compaction of fetal myocardium [9]. The utilization of the CRISPR/Cas quality altering framework conveyed by non-incorporating viral vectors may be a fascinating methodology for the hereditary treatment of Hutchinson Gilford Progeria Syndrome (HGPS) by using gene therapy [10,11]. One of the methodologies for quality quieting is time arrangement ponders on cells. It applies stimulators of the cells at distinctive time focuses and analyzes the phenotypes in human cells and control cells [12,13].

The studies on the quality articulation of IL-6 are particularly required if there should arise an occurrence of osteoporosis in which one of pathomechanisms of malady is the unnecessary arrival of pro inflammatory cytokines which prompt demineralization of the skeleton [14,15]. The expanded rate of leukemia's happening in retroviral quality treatment clinical trials for X-SCID patients, because of the irregular mix of vectors close oncogenes, remains a noteworthy obstacle to the clinical utilization of this methodology [16-18]. In addition to conventional gene therapy, some studies with heterologous therapy shown that PAH expression in tissues other than liver) have been developed for Phenyl Ketone Urea (PKU) [19-23]. During acute HBV and HCV infection, robust CD4+ and CD8+ cellular responses against multiple viral proteins lead to spontaneous viral clearance. The inability to mount such strong virus-specific response causes chronic illness. Persistence of virus specific and non-specific immune cells, during chronic illness, is responsible for the observed inflammatory responses [24,25]. Genomic DNA was extricated from venous blood with an economically accessible pack, Omega Blood DNA Midi Kit (D3494-01), utilizing the manufacturing protocols [26]. Cystic Fibrosis (CF) presents as phenotypic heterogeneity of the clinical indications that are balanced by cystic fibrosis transmembrane controller (CFTR) change the earth and modifier. Our gathering has mulled over the clinical balance of CF by hopeful modifier qualities that impact drug reactions, the development of the lung and digestive ailment in CF, and CF-related comorbidities [27,28]. Quality transduction into regions with undifferentiated organisms by straightforwardly overseeing a vector into the intestinal tract in the wake of uprooting intestinal bodily fluid gives off an impression of being an exceptionally helpful system for quality treatment amid radiation treatment [29]. Syndactyly of the foot is a typical inborn anomaly in which there is diligence of webbing between adjoining toe, can likewise happen alongside other conception imperfections including the skull, face, and bones [30,31]. In gene therapy, quality of hobby is bundled inside a transporter particle. This transporter can be a designed infection, liposome, arginine-united cyctamine bisacrylamide diamino hexane polymer (ABP) or a nano-complex [32]. The most famous physical hereditary change system is electroporation. This is because of its brisk ness, ease, and

straightforwardness notwithstanding when it has a low effectiveness, requires difficult conventions for recovery after hereditary change, and must be connected to protoplasts [33,34].

Eosinophilic gastroenteritis (EG) is an uncommon ailment, portrayed by eosinophilic penetration of the intestinal divider. The definite frequency is obscure. The malady influences all races and any age bunch from outset to maturity, albeit in grown-ups, it has a crest rate in the third to fifth decade [35-38]. Eosinophilic gastroenteritis (EG) is an uncommon sickness, portrayed by eosinophilic penetration of the intestinal divider. The definite rate is obscure. The malady influences all races and any age bunch from earliest stages to seniority, albeit in grown-ups, it has a top occurrence in the third to fifth decade [39-44]. The utilization of gene therapy is quickly making strides in the field of immunotherapy and the revision of monogenetic issue [45-52]. Gene therapy may eventually become applicable to the congenital forms of NDI [53-61]. Gene therapy is also used for treatment of brain genetic disorders [62-78]. Intestinal carcinogenesis is the last result of a multi-step procedure coming about because of hereditary changes that are affected by natural elements (particularly dietary segments) and host related variables (cytokines and hormones including sex steroid hormones). Be that as it may, varieties in disease occurrence among and inside of populaces with comparable dietary examples recommend that the overwhelming pathogenetic component is spoken to by the quality intervened individual reaction, through the outflow of distinctive protein and metabolite designs [79-87]. In any case, in spite of this shameful result, quality treatment mediations have increased expanded consideration, so that to date growth makes more than 60% out of all progressing clinical quality treatment trials around the world, trailed by monogenetic and cardiovascular infections [88-100].

REFERENCES

1. [Hsueh Y, et al. Corneal Neovascularization as a Target for Nucleotide-Based Therapies. J Clin Exp Ophthalmol. 2015;6:409.](#)
2. [Zhang C. The WD40 Repeat Protein Mutations: Genetics, Molecular Mechanisms and Therapeutic Implications. J Genet Syndr Gene Ther. 2014;5:252.](#)
3. [Hermonat PL. Improving AAV Gene Therapy: Graduating From Transgene Expression to Disease-Specificity. Clon Transgen. 2014;3:e114.](#)
4. [Graziano ACE and Cardile V. Genetic Test and Gene Therapy for Krabbe Disease: An Update. Gene Technology. 2015; 4:118.](#)
5. [Kajhoj TQ, et al. Test of Critical Steps towards a Combined Cell and Gene Therapy Approach for the Treatment of Duchenne Muscular Dystrophy. J Mol Genet Med. 2015;9:160.](#)
6. [Altaner C. Prodrug Gene Therapy for Cancer Mediated by Mesenchymal Stem/Stromal Cells Engineered to Express Yeast Cytosine deaminase::Uracil phosphoribosyltransferase. J Stem Cell Res Ther. 2015;5:264.](#)
7. [Awan H, et al. Segregation of Malignant Hematological Disease in Families with Malignant Lymphoma. J Genet Syndr Gene Ther. 2014;5:249.](#)
8. [Peltier L, et al. Development of a New Third-Party Unit for Adult Stem Cell Transplantation using Clinical-Grade Rejected Cord Blood Units. J Genet Syndr Gene Ther. 2015;6:254.](#)
9. [Peter Morcos N, et al. Left Ventricular Non-Compaction: Current Controversy and New Insights. J Genet Syndr Gene Ther 2015;6:255.](#)
10. [Arancio W, et al. Hutchinson Gilford Progeria Syndrome: A Therapeutic Approach via Adenoviral Delivery of CRISPR/cas Genome Editing System. J Genet Syndr Gene Ther. 2015;6:256.](#)
11. [Pizzolanti G, et al. Identification of Novel Wsf1 Mutations in a Sicilian Child with Wolfram Syndrome. J Genet Syndr Gene Ther. 2014;5:245.](#)
12. [Youming Zhang and Yun Zhang. Functional Dissection of Novel Genes on Complicated Diseases. J Genet Syndr Gene Ther. 2015;6:e128.](#)
13. [Wang DQH, et al. Familial Mediterranean Fever: From Pathogenesis to Treatment. J Genet Syndr Gene Ther. 2014;5:248.](#)
14. [Schaefer E, Minoux M, Lauer J, Pelletier V, Schmittbuhl, et al. A Novel Mutation Involving the Initiation Codon of FGF3 in a Family Described with Complete Inner Ear Agenesis, Microtia and Major Microdontia \(LAMM Syndrome\). J Genet Syndr Gene Ther 2014; 5:251.](#)
15. [Massart F, Bertelloni S, Miccoli M, Baggiani A. Height Outcome of the Recombinant Human Growth Hormone Treatment in Subjects with Noonan Syndrome: A Meta-Analysis. J Genet Syndr Gene Ther. 2014;5: 238.](#)

16. [Rahnama M, Jastrzebska-Jamrogiewicz I, Jamrogiewicz R and Trybek G The Analysis of Hormone Replacement Therapy Influence on Il-6 Expression and Mandible T-Score of Postmenopausal Women. J Genet Syndr Gene Ther. 2015;6:253.](#)
17. [Venuti A, Lopalco L Tackling HIV: Genetic vs. Immune CCR5 targeting. J AIDS Clin Res 5:344.](#)
18. [Elisei R, Molinaro E, Agate L, Bottici V, Viola D, et al. Ret Oncogene and Thyroid Carcinoma. J Genet Syndr Gene Ther. 2014;5: 214.](#)
19. [Yoshimitsu M, Higuchi K, Arima N, Medina JA, Takenaka T Successful Induction of Pluripotent Stem Cells From a Fabry Disease Mouse Model: Toward the Development of Safe Lentiviral Gene Therapy. J Stem Cell Res Ther. 2015;5:259.](#)
20. [Grigoriadou M, Schulpis KH, Kokotas H Molecular Genetics and Gene Therapy Aspects of Phenylalanine Hydroxylase \(PAH\) Related Hyperphenylalaninemias. J Genet Syndr Gene Ther. 2015;5:e127.](#)
21. [Schaefer E, Minoux M, Lauer J, Pelletier V, Schmittbuhl J, et al. A Novel Mutation Involving the Initiation Codon of FGF3 in a Family Described with Complete Inner Ear Agenesis, Microtia and Major Microdontia \(LAMM Syndrome\). J Genet Syndr Gene Ther. 2014;5:251.](#)
22. [Grigoriadou M, Schulpis KH, Kokotas H Molecular Genetics and Gene Therapy Aspects of Phenylalanine Hydroxylase \(PAH\) Related Hyperphenylalaninemias. J Genet Syndr Gene Ther 5:e127.](#)
23. [Nadim N, Mais-Nadim N, Nasser T Triad, A Useful Marker for Leukodystrophies Diagnosis. J Genet Syndr Gene Ther 2014;5: 242.](#)
24. [Zakaria MK, Sankhyan A, Ali A, Fatima K, Azhar E, et al. HBV/HCV Infection and Inflammation. J Genet Syndr Gene Ther. 2014;5: 241](#)
25. [Ernst G, Auteri S, Caro F, Colodenco D, Fernandez M, et al. Significant Increase of IL-8 Sputum Levels in Treatment Resistant Severe Asthma Compared with Difficult to Treat Severe Asthma Patients. J Genet Syndr Gene Ther. 2014;5:218.](#)
26. [Lin H, Fu R, Zhang X, Yao B, Ye J, et al. A New Homozygous ABCB4 Mutation Identified in Two Chinese Siblings Based on Exome Sequencing. J Genet Syndr Gene Ther 5: 243.](#)
27. [de Lima Marson FA, Zimmermann LA, Ribeiro JD, Bertuzzo CS ADIPOR2 Polymorphisms in Cystic Fibrosis are Potential Modifiers of Clinical Severity. J Genet Syndr Gene Ther. 2014;5:246.](#)
28. [Genel S, Emanuela F, Lucia SM, Daniel S, Corina M Cystic Fibrosis - An Open Book that must be Always Updated. J Genet Syndr Gene Ther. 2014;5:224.](#)
29. [Fumikazu Koyama, Kazuaki Uchimoto, Hisao Fujii, Hirofumi Hamada, Kazuo Ohashi, et al. Adenovirus-Mediated Bcl-XL Gene Therapy Combined with Pronase Treatment Protects the Small Intestine from Radiation-Induced Enteritis in Mouse Model. J Genet Syndr Gene Ther. 2014;5:239.](#)
30. [Avina Fierro JA and Hernandez Avina DAA Case of Complete Cutaneous Syndactyly of the Toes with Non-Syndromic Phenotype. J Genet Syndr Gene Ther. 2014;5:240.](#)
31. [Ikehara S, Li M, Shi M, Cui Y, Guo K, et al. Reconstitution with Bone Marrow Cells is Consistently Defective in the Tibia of Aged Monkeys. J Genet Syndr Gene Ther. 2014;5:219.](#)
32. [Rao GHR, Gandhi PG, Sharma V Clinical Complications of Type- 2 Diabetes Mellitus in South Asian and Chinese Populations: An Overview. J Diabetes Metab. 2014;5:420.](#)
33. [Rivera AL, Gomez-Lim M, Fernandez F, Loske AM Genetic Transformation of Cells using Physical Methods. J Genet Syndr Gene Ther. 2014;5:237.](#)
34. [Hassan AIT Benhassou, Nadia Bouchoutrouch, Youssef Amar, Hassan Sefrioui Hereditary Breast Cancer in Moroccan Populations: BRCA1 & BRCA2 at the Glance. J Genet Syndr Gene Ther. 2014;5:234.](#)
35. [Müller M, Keller KM, Stallmann S, Eckardt AJ Clinicopathologic Findings in Eosinophilic Gastroenteritis: A German Case Series. J Genet Syndr Gene Ther. 2014;5:230.](#)
36. [Ishiyama Y, Fujimura M, Kasahara K Eosinophilic Bronchial Disorders Presenting Chronic Cough; Atopic Cough, Cough Variant Asthma and Non-Asthmatic Eosinophilic Bronchitis. J Genet Syndr Gene Ther. 2014;5:217.](#)
37. [García MM, Teira BGEosinophilic Esophagitis, A Rising Pathology. J Genet Syndr Gene Ther. 2014;5: 215.](#)

38. [Nosó S, Kawabata Y, Babaya N, Hiromine Y, Kawasaki E, et al. Association Study of MAFA and MAFB Genes Related to Organ-Specific Autoimmunity, with Susceptibility to Type-1 Diabetes in Japanese and Caucasian Populations. J Genet Syndr Gene Ther. 2013;4:204.](#)
39. [Müller M, Keller KM, Stallmann S, Eckardt AJ. Clinicopathologic Findings in Eosinophilic Gastroenteritis: A German Case Series. J Genet Syndr Gene Ther. 2014;5:230.](#)
40. [Kumar A. Genetics: A Computational Approach, 5th Edition by Benjamin A. Pierce. J Genet Syndr Gene Ther. 2014;5:229.](#)
41. [Foldvari M. Nanopharmaceuticals Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedicine Biotherapeutic Discov. 2014;4: e135.](#)
42. [Bunker DJ. Delivery Techniques in Gene Therapy: A Brief Overview. J Phys Chem Biophys 4:147.](#)
43. [Armengot M, Garin L, Peiro T, Milara J, Cortijo J. Eosinophils and Airway Inflammation. J Genet Syndr Gene Ther. 2014;5:220.](#)
44. [Garaigorta M, Nantes Ó, Arán A, Rodríguez C, Zabalza J. Circumferential Esophageal Dissection Treated Conservatively in a Young Patient with Eosinophilic Esophagitis. J Genet Syndr Gene Ther. 2014;5: 210.](#)
45. [Viswanathan A, Wang G. Enhanced Expression of N-Formyl Peptide Receptor in Mesenchymal Stem Cells Facilitates Homing to Inflammatory Lungs. J Genet Syndr Gene Ther. 2014;5:227.](#)
46. [Mattioli AV, Pennella S, Bonetti LR, Migaldi M, Farinetti A, et al. Stem Cells Transplantation in Myocardial Tissue Induces Proarrhythmic Effects and Promotes Reperfusion. Comparison between Intramyocardial and Intravenous Approach. J Genet Syndr Gene Ther. 2014;5:226.](#)
47. [Berumen LC, García AG. 5-HT_{2A} Receptors during Ontogeny. J Genet Syndr Gene Ther. 2014;5:e126.](#)
48. [Berkinbayev S, Rysuly M, Mussayev A, Blum K, Baitasova N, et al. Apolipoprotein Gene Polymorphisms \(APOB, APOC111, APOE\) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan. J Genet Syndr Gene Ther. 2014;5:216.](#)
49. [Kobayashi K, Hagiwara K. Treatment Guideline for Advanced NSCLC Based on Driver Gene Mutations. J Genet Syndr Gene Ther. 2014;5: 212.](#)
50. [Tucker ME, Kalb FM, Escobar L. Infant Spinocerebellar Ataxia Type 27: Early Presentation Due To a 13q33.1 Microdeletion Involving the FGF14 Gene. J Genet Syndr Gene Ther. 2013;4:208.](#)
51. [Militti L, Alfonsi M, Palka C, Soranno A, Calabrese G, et al. A Mosaic Ring Chromosome 21 in a Patient with Mild Intellectual Disability not Evidenced by Array-Cgh. J Genet Syndr Gene Ther. 2013;4:207.](#)
52. [Brentnall AR, Evans DG, Cuzick J. Value of Phenotypic and Single-Nucleotide Polymorphism Panel Markers in Predicting the Risk of Breast Cancer. J Genet Syndr Gene Ther. 2013; 4:202.](#)
53. [Procino G, Milano S, Carmosino M, Gerbino A, Bonfrate L, et al. Hereditary Nephrogenic Diabetes Insipidus: Molecular Basis of the Defect and Potential Novel Strategies for Treatment. J Genet Syndr Gene Ther. 2014;5:225.](#)
54. [Riccardi VM. Hiding in Plain Sight: A Consideration of NF1-Associated Hypovitaminosis D and its Treatment. J Genet Syndr Gene Ther. 2014;5:223.](#)
55. [Ahmad I, Shahin R. Autologous Gene Therapy - A Proactive Approach to Cancer Critique. J Cancer Sci Ther. 2014;R1:001.](#)
56. [Kataoka H, Kitauti T, Kobayashi Y, Ueno S. Four-Year Course of Serum and Cerebrospinal Fluid Antibody Titers in a Patient with Anti-NMDAR Encephalitis. J Genet Syndr Gene Ther. 2014;5:221.](#)
57. [Riccobono D, François S, Valente M, Forcheron F, Drouet M. Advances in Stem Cell Therapy: Specific Applications in the Treatment of Cutaneous Radiation Syndrome. J Stem Cell Res Ther. 2014;4:186.](#)
58. [Zhang Y, Yao X. The Recent Advances and Future Perspectives of Personalized Medicine. J Genet Syndr Gene Ther. 2014;5:e125.](#)
59. [Oliveira JT, Lopes FRP, de Almeida FM, Martinez AMB. Gene Therapy in Rodents Models of Traumatic Peripheral Nerve Injury. J Cell Sci Ther. 2014;5:156.](#)
60. [Braverman ER, Berman MO, Kreuk F, Kerner M, Dushaj K, et al. Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory](#)

- [Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy MHRT\). J Genet Syndr Gene Ther. 2013;4:206.](#)
61. [Powers JM, Trobridge GDIentification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies. J Stem Cell Res Ther. 2013;S3:004.](#)
 62. [Blum K, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, et al.A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain. J Genet Syndr Gene Ther. 2014;5: 213.](#)
 63. [Fragale A, Marsili G, Battistini AGenetic and Epigenetic Regulation of Interferon Regulatory Factor Expression: Implications in Human Malignancies. J Genet Syndr Gene Ther. 2013;4:205.](#)
 64. [Baird FJ, Bennett CLMicrotubule Defects and Neurodegeneration. J Genet Syndr Gene Ther. 2013;4:203.](#)
 65. [Shu XGene Therapy for X-Linked Retinitis Pigmentosa. Clon Transgen. 2013;3:e108.](#)
 66. [Izquierdo Álvarez S, Urrechaga Igartua E, Escanero Marcén JF Review and actualizations of Molecular Genetic Diagnosis, Symptoms, and diagnostic strategies of Hereditary Hemochromatosis. J Genet Syndr Gene Ther. 2013;4:184.](#)
 67. [de Tommaso M, Serpino C, Cormio C, Scirucchio V, Franco G, et al.EEG Correlates of Emotional Experience in Huntingtonâ€™s Disease. J Genet Syndr Gene Ther. 2013;4:199.](#)
 68. [Barone M, Leo DiEstrogen Receptor beta in Colorectal Cancer Prevention: Do we have Conclusive Proof? J Genet Syndr Gene Ther. 2013;4: 201.](#)
 69. [Malecki M, Dahlke J, Haig M, Wohlwend L, Malecki REradication of Human Ovarian Cancer Cells by Transgenic Expression of RecombinantDNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter:Novel Strategy for Targeted Therapy of Cancer. J Genet Syndr Gene Ther. 2013;4 6\): 152: 110.](#)
 70. [Tavian D, Missaglia S, DiMauro S, Bruno C, Pegoraro E, et al.A Late-Onset Case of Neutral Lipid Storage Disease with Myopathy, Dropped Head Syndrome, and Peripheral Nerve Involvement. J Genet Syndr Gene Ther. 2013;4:198.](#)
 71. [Chandran S, Yap F, Hussain KGenetic Disorders Leading to Hypoglycaemia. J Genet Syndr Gene Ther. 2013;4:192.](#)
 72. [Melloni G, Bedeschi MF, Cesaretti C, Milani D, Ronzoni L, et al.Autosomal Dominant Diseases are too Often Overlooked in the Parents of Affected Children: Report of Six Cases. J Genet Syndr Gene Ther. 2013; 4:190.](#)
 73. [Khan G, Denniss F, Mills KI, Pulford K, Guinn BPA SD1: A Promising Target for the Immunotherapy of Haematological Malignancies. J Genet Syndr Gene Ther. 2013;4:186.](#)
 74. [Guglielmi V, Voermans NC, Gualandi F, Van Engelen BG, Ferlini A, et al.Fourty-Four Years of Brody Disease: It is Time to Review. J Genet Syndr Gene Ther. 2013;4:181.](#)
 75. [Novak J, Lambiasi PDTreatment of Electrical Storm with Amiodarone in Brugada Syndrome- an Unexpected Protective Effect. J Genet Syndr Gene Ther. 2013;4:176.](#)
 76. [Cavallini GM, Forlini M, Gramajo AL, Brombin A, Torlai G, et al.Optic Nerve Aplasia and Microphthalmos: A Case Report. J Genet Syndr Gene Ther. 2013;4:175.](#)
 77. [Russo L, Cifarelli RA, Venere BD, Sgambato A, Susi M, et al.Novel Germline Mutation Q1260X\) in APC Gene Causes Familial Adenomatous Polyposis in a Ukrainian Family. J Genet Syndr Gene Ther. 2013;4:197.](#)
 78. [Li M, Ikehara SAutoimmune Disease Treatment with Stem Cell Transplantation. J Genet Syndr Gene Ther. 2013;4:174.](#)
 79. [Qing-quan C, Feng G, Ze-hao Z, Zhi-bo Z, Qi-cai L, et al.Trypsin-antitrypsin Imbalance in Immune Escape and Clonal Proliferation of Pancreatic Cancer. J Genet Syndr Gene Ther . 2013;4:200.](#)
 80. [Conese MGene Therapy Gets its Momentum through the Marketing of an Engineered Virus to Treat Lipoprotein Lipase Deficiency. Adv Genet Eng . 2013;2:e104.](#)
 81. [Naoe M, Ogawa Y, Hasebe Y, Fuji K, Iwamoto S, et al.Gammadelta T Cells may Function as Carrier Vehicles in Adenovirus Vector-based Gene Therapy. J Cancer Sci Ther. 2013;5:384-390.](#)
 82. [Formica V, Cereda V, Nardecchia A, Morelli C, Lucchetti J, et al.Are Fragment C Gamma Receptor FCGR\) Germline Polymorphisms Predictive Biomarkers in Metastatic Colorectal Cancer? J Genet Syndr Gene Ther. 2013;4:193.](#)

83. [Caffo M, Caruso G, Passalacqua M, Angileri FF, Tomasello F Antisense Oligonucleotides Therapy in the Treatment of Cerebral Gliomas: A Review. J Genet Syndr Gene Ther. 2013;4:194.](#)
84. [Rajab K, Nelson P, Keung EZ, Conrad CSuicide Gene Therapy against Cancer. J Genet Syndr Gene Ther. 2013;4:187.](#)
85. [Kato F, Yagi T, Fujieda T, Kondo Y, Yamaguchi T, et al.Hemagglutinating Virus of Japan Envelope Vectors as High-Performance Vehicles for Delivery of Small RNAs. J Genet Syndr Gene Ther. 2013;4:178.](#)
86. [Falkenhagen A, Ameli M, Asad S, Read SE, Joshi S Gene Therapy Using a Secreted Single Chain Variable Fragment Targeting CCR5 to Inhibit HIV Infection. J Antivir Antiretrovir. 2013;5: 085-091.](#)
87. [Yamamoto T, Ueki HKoebner Phenomenon in Rheumatoid Arthritis. J Genet Syndr Gene Ther. 2013;4:173](#)
88. [Christalena S, Eirini T, Olga F, Despina M, Helen Flridocyclitis in a Female Patient with a Variant of Turner Syndrome. J Genet Syndr Gene Ther. 2013;4:196.](#)
89. [Kuliev A, Verlinsky O, Rechitsky S Preimplantation Hla Typing- Practical Tool for Stem Cell Transplantation Treatment of Congenital and Acquired Disorders. J Genet Syndr Gene Ther. 2013;4:195.](#)
90. [Vageli DP, Papamichali R, Kambosioras K, Papandreou CN, Koukoulis GKMismatch DNA Repair hMSH2, hMLH1, hMSH6 andhPMS2 mRNA Expression Profiles in Colorectal Carcinomas J Genet Syndr Gene Ther. 2013;4:191.](#)
91. [Hartwig FPSNP-SNP Interactions: Focusing on Variable Coding for Complex Models of Epistasis. J Genet Syndr Gene Ther. 2013;4:189.](#)
92. [Annicchiarico G, Morgese MG, Fiore T, Mauro S, Garofalo L, et al.Hla Typing in Epidermolysis Bullosa Patients: Relevancy to Gluten Sensitivity. J Genet Syndr Gene Ther. 2013;4:182.](#)
93. [Ropero P, González-Borrachero ML, Peña A, González FA, de la FGF, et al.Hb Nunobiki \[\$\alpha_2\$ 141HC3\] Arg→Cys; HBA2:c.424C>T\] in Spain: Mutation de novo or Acquired? J Genet Syndr Gene Ther . 2013;4:180.](#)
94. [Marciello F, Somma CD, Savastano S, Camera L, Volante M, et al.Combined Biological Therapy is Effective to Control all Neuroendocrine Tumor Manifestations in a Patient with MEN1 Syndrome. J Genet Syndr Gene Ther. 2013;4:179.](#)
95. [Adams M, Jenney M, Lazarou L, White R, Birdsall S, et al.Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome. J Genet Syndr Gene Ther. 2013;4:177.](#)
96. [Tanaka M, Matsumoto T, Morisaki K, Kyuragi R, Fujino Y, et al.Efficacy and Safety of DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: Study Protocol of a Randomized Phase IIb Trial. J Clin Trials 3:138.](#)
97. [Voutetakis A, Settas N, Dacou-Voutetakis C Genetically Determined Central Hypothyroidism. J Genet Syndr Gene Ther. 2013;4:172.](#)
98. [Tuppurainen L, Sallinen H, Hakkarainen H, Liimatainen T, Hassan M, et al.Functional MRI Measurements to Predict Early Adenoviral Gene Therapy Response in Ovarian Cancer Mouse Model. J Genet Syndr Gene Ther. 2013;4:171.](#)
99. [Forlini M, Gramajo AL, Rejdak R, Prokopiuk A, Levkina O, et al.Retropupillary Iris-Claw Intraocular Lens in Ectopia Lentis Due to Marfan Syndrome. J Genet Syndr Gene Ther . 2013;4:170.](#)
100. [Zarogoulidis P, et al.Suicide Gene Therapy for Cancer Current Strategies. J Genet Syndr Gene Ther. 2013;4:139.](#)